McKesson Deep-Dive ($MCK): A 20% Panic, and a Structural Margin of Safety

Hey everyone,

I wanted to share a quick fundamental thesis on McKesson Corporation ($MCK) following its recent \~20% correction from its peak. I've pasted the link at the bottom of this post for anyone who wants to read more in-depth. The stock dropped from nearly $1,000 down to around $740, primarily driven by a top-line revenue miss in Q4 of fiscal 2026. However, looking under the hood, the structural thesis for this long-term compounder remains incredibly intact.

Here are the key pillars of the value thesis:

1. A Rational Oligopoly Moat

McKesson, along with Cencora and Cardinal Health, control a vast majority of the U.S. pharmaceutical distribution market. Their value proposition to hospital networks and pharmacies is absolute supply chain reliability and working capital optimization. A community pharmacy cannot afford to hold millions of dollars of inventory on its balance sheet; McKesson handles the logistics, creating massive customer switching costs.

2. Asset-Light Capital Allocation & Cannibalization

Despite operating on razor-thin margins (roughly 1.5% operating margins), MCK is an incredibly capital-light business model that generated $5.4 billion in free cash flow in FY 2026. Management's capital allocation strategy is perfectly aligned with shareholders, with compensation tied directly to ROIC and Adjusted EPS. Rather than empire-building via low-return projects, they aggressively buy back stock. Over the last 20 years, McKesson has reduced its outstanding share count by over 60%, creating a permanent tailwind for per-share metrics.

3. Higher-Margin Segment Pivot

The market is treating MCK like a stagnant legacy distributor, but management is aggressively shedding low-margin, non-core assets (like their recent European divestitures and selling Rexall/Well.ca). They are pivoting capital into their Oncology and Multi-Specialty segment, which grew revenues by 31% and operating profit by 53% in FY 2026. This segment boasts double the operating margins (2.27%) of their core pharmaceutical distribution business.

4. The Valuation & Margin of Safety

Using highly conservative assumptions where growth completely stagnates over the next four years, drops to 2% in year four, and hits 0% by year five with a 0% terminal growth rate, my DCF model places McKesson's conservative intrinsic value at $885 a share (an 18% upside to a worst-case scenario).

If you adjust the terminal growth rate to a more realistic, albeit still very conservative, 2% (in line with long-term inflation targets), the intrinsic value jumps to $1,275 per share, representing a 70% upside.

Summary:

• Tailwinds: Structural demand from an aging U.S. demographic and massive volume acceleration from GLP-1 agonists.

• ROIC: Reached a colossal 70% last year.

• Shareholder Returns: The board just approved a fresh $5B share buyback program at the end of Q4.

I'd love to hear your thoughts on the competitive dynamics against Cardinal/Cencora and whether you think the recent top-line miss is structural or just temporary noise.

If you want to read the full breakdown, or dive more deeply into this name, you can read my full deep-dive here: [https://mulberryfinancial.substack.com/p/mckesson-mck-stock-analysis-deep-dive-2026?r=4af6n2](https://mulberryfinancial.substack.com/p/mckesson-mck-stock-analysis-deep-dive-2026?r=4af6n2)

**DISCLAIMER**

The content provided here is for informational and educational purposes only and does not constitute financial, investment, legal, or tax advice. The information contained herein is general in nature and does not take into account your personal financial situation, risk tolerance, or investment objectives.